drugset / Trial / NCT00128245
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
RandomizedParallel-groupDouble-blindTreatment
Summary
This study evaluates the efficacy and safety of 2 doses of pimecrolimus (0.3% and 1%) ophthalmic suspension in a moderate to severe population of keratoconjunctivitis sicca (KCS, dry eye syndrome) patients.
Timeline
- Start
- 2004-09
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimecrolimus | Small molecule | 0.3 % | — |
| Subject | Pimecrolimus | Small molecule | 1 % | — |